BioWorld. Link to homepage.

Clarivate
  • BioWorld
  • BioWorld Science
  • BioWorld Asia
  • Data Snapshots
    • Biopharma
    • Medical technology
    • Infographics: Dynamic digital data analysis
    • Index insights
    • NME Digest
  • Special reports
    • Infographics: Dynamic digital data analysis
    • Trump administration impacts
    • Under threat: mRNA vaccine research
    • BioWorld at 35
    • Biopharma M&A scorecard
    • Bioworld 2025 review
    • BioWorld MedTech 2025 review
    • BioWorld Science 2025 review
    • Women's health
    • China's GLP-1 landscape
    • PFA re-energizes afib market
    • China CAR T
    • Alzheimer's disease
    • Coronavirus
    • More reports can be found here

BioWorld. Link to homepage.

  • Sign In
  • Sign Out
  • My Account
Subscribe
BioWorld - Tuesday, February 10, 2026
Home » Blogs » BioWorld MedTech Perspectives » Congress enjoys a rare moment of harmony with passage of FDA user fee act

BioWorld MedTech Perspectives
BioWorld MedTech Perspectives RSS FeedRSS

Medical technology

Congress enjoys a rare moment of harmony with passage of FDA user fee act

June 7, 2012
By Holland Johnson

With all the acrimony between Democrats and Republicans in Congress these days, it was truly edifying to see lawmakers on both sides of the aisle agreeing on a piece of legislation - and in the healthcare sector no less - the FDA user fee reauthorization act.

Last week, the U.S. House of Representatives reaffirmed passage of the FDA user fee reauthorization act in a 387-5 roll call vote taken after an earlier voice vote.

The House affirmation followed close on the heels of the earlier congenial vote on the act by the Senate, a nearly unanimous 96-1 approval.

The groundwork for this quick approval came about back in February when industry stakeholders and FDA representatives came to terms on a tentative version of the agreement. At that time the parties agreed in principal to the new five-year user fee agreement for medical devices, and the $595 million agreed to was more than double the amount collected under the prior user fee agreement, which netted the agency less than $290 million. As a sweetener for all the extra money from industry, FDA agreed to measure device reviews by total elapsed time rather than just the number of days an application is on the agency's clock, a much more rigid standard.

Don’t expect the two chambers to partake in a spontaneous rendition of the spiritual song Kumbaya just because they accomplished the passage of some legislation though. As a matter of fact, shortly after this effort, the partisan rancor erupted again; this time over the House’s planned passage of a repeal of the 2.3% device tax.

Republicans on the U.S. House of Representatives' Ways & Means Committee voted to repeal the excise tax included in the Affordable Care Act on May 31. The full House is expected to take up the bill June 7 or 8. The tax is expected to raise $29 billion starting in 2013 to help pay for insurance for the uninsured.

And while the device tax repeal bill is expected to pass the full House, it faces certain defeat in the Senate, where parallel legislation introduced by Republican Senators Orrin Hatch and Scott Brown lacks bipartisan authors.

Well so much for peace, love and understanding.

Popular Stories

  • Today's news in brief

    BioWorld
    BioWorld briefs for Feb. 9, 2025.
  • Brain illustration

    MJFF grant supports Bexorg’s translational biomarker work

    BioWorld Science
    Bexorg Inc. has been awarded a research grant from The Michael J. Fox Foundation for Parkinson’s Research (MJFF) through the Targets to Therapies initiative to...
  • Liver anatomy illustration

    KLF15 shows potential as marker, target for cholangiocarcinoma

    BioWorld Science
    Researchers at the Biodonostia Health Research Institute reported on the role of KLF15 in cholangiocarcinogenesis and its potential as a therapeutic target in...
  • Illustration of SCAN in Parkinson’s vs healthy subcortex

    SCAN is core circuit affected in Parkinson’s disease

    BioWorld Science
    Parkinson’s disease (PD) is a neurodegenerative disorder that affects movement, and tremor is one of its signatures. But it is a much more wide-ranging disorder,...
  • Woman and 3D brain

    Astellas’ ASP-2246 shows promise in stroke management

    BioWorld Science
    Astellas Pharma Inc. recently presented data regarding ASP-2246, a drug candidate comprised of an mRNA encoding the transcription factor NeuroD1 encapsulated in...
  • BioWorld
    • Today's news
    • Analysis and data insight
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Medical technology
    • Newco news
    • Opinion
    • Regulatory
  • BioWorld Science
    • Today's news
    • Biomarkers
    • Cancer
    • Conferences
    • Endocrine/metabolic
    • Immune
    • Infection
    • Neurology/psychiatric
    • NME Digest
    • Patents
  • BioWorld Asia
    • Today's news
    • Analysis and data insight
    • Australia
    • China
    • Clinical
    • Deals and M&A
    • Financings
    • Newco news
    • Regulatory
    • Science
  • More
    • About
    • Advertise with BioWorld
    • Archives
    • Article reprints and permissions
    • Contact us
    • Cookie policy
    • Copyright notice
    • Data methodology
    • Infographics: Dynamic digital data analysis
    • Index insights
    • Podcasts
    • Privacy policy
    • Share your news with BioWorld
    • Staff
    • Terms of use
    • Topic alerts
Follow Us

Copyright ©2026. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing